Risk factors
Vaxcyte (PCVX) risk factors
Item 1A of every Vaxcyte, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors69 risks10 new12 dropped17 reworded
Vaxcyte added risks regarding new tax legislation, international trade policy tariffs on pharmaceuticals, and generative AI regulations. The company also updated disclosure controls and refined references to its vaccine pipeline products.
Filed Feb 24, 2026 - FY2024 10-K risk factors71 risks
Vaxcyte has no commercial products and relies entirely on clinical-stage vaccine candidates like VAX-31 and VAX-24. The company holds $3,134.7 billion in cash, cash equivalents, and investments as of December 31, 2024. Operations depend heavily on a cell-free manufacturing platform and third-party contract manufacturers like Lonza.
Filed Feb 25, 2025